| Morschhauser, Franck |
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
|
|
| Recruiting | 3 | 66 | Europe, Canada, US, RoW | tabelecleucel, tab-cel®, ATA129, EBV-CTL | Atara Biotherapeutics | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | 08/25 | 06/27 | | |
|
RELEVANCE , NCT01650701 / 2011-002792-42: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma |
|
|
| Completed | 3 | 1030 | Europe, Canada, RoW | Rituximab, mabthera, rituxan, Lenalidomide, Revlimid, Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine | The Lymphoma Academic Research Organisation, Celgene Corporation | Follicular Lymphoma | 05/17 | 04/24 | | |
|
|
| Completed | 3 | 255 | Japan, US | Rituximab, Lenalidomide, Revlimid, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine | Celgene, The Lymphoma Academic Research Organisation | Follicular Lymphoma | 04/24 | 04/24 | | |
|
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 74 | Europe | Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant | The Lymphoma Academic Research Organisation | Aggressive Non-Hodgkin Lymphoma | 06/19 | 03/25 | | |
NCT03766763: Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a |
|
|
| Active, not recruiting | 2 | 82 | Europe | Venetoclax | French Innovative Leukemia Organisation | Chronic Lymphoid Leukemia | 01/22 | 04/30 | | |
ALYCANTE, NCT04531046: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 62 | Europe | axicabtagene ciloleucel, axi-cel | The Lymphoma Academic Research Organisation | B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 04/22 | 06/26 | | |
| Active, not recruiting | 2 | 67 | Europe | Obinutuzumab, gazyva, RO7082859, glofitamab | The Lymphoma Academic Research Organisation | Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma | 01/23 | 03/26 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
NCT06271057: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
|
|
| Recruiting | 2 | 65 | Europe | golcadomide, BMS-986369, CC-99282 | The Lymphoma Academic Research Organisation, Lymphoma Study Association | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | 01/26 | 10/27 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
NCT01582776 / 2011-005150-62: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma |
|
|
| Completed | 1/2 | 317 | Europe | Lenalidomide and GA101, Revlimid, Obinutuzumab | The Lymphoma Academic Research Organisation | Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) | 07/18 | 05/22 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
| Recruiting | 1/2 | 184 | Europe, US, RoW | IPH6501 | Innate Pharma | Non Hodgkin Lymphoma | 12/28 | 12/28 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
ALK-OBS, NCT03603847: Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma |
|
|
| Completed | N/A | 41 | Europe | | The Lymphoma Academic Research Organisation, Hôpital Necker-Enfants Malades, Fondation ARC, Pfizer, Takeda | Anaplastic Large Cell Lymphoma, ALK-Positive | 06/23 | 06/23 | | |
NCT05529524: Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) |
|
|
| Completed | N/A | 6 | Europe | | The Lymphoma Academic Research Organisation, Roche Pharma AG | Follicular Lymphoma | 01/24 | 01/24 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
| Recruiting | N/A | 204 | Europe | Chemotherapy + follow up, Chemotherapy + ASCT + follow up | Hospices Civils de Lyon | Peripheral T Cell Lymphoma | 04/28 | 04/28 | | |
| NESTE, Eric VAN DEN |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
| Active, not recruiting | 2 | 74 | Europe | Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant | The Lymphoma Academic Research Organisation | Aggressive Non-Hodgkin Lymphoma | 06/19 | 03/25 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Lambert, Catherine |
NCT05606640: Gaining Insight Into the Complexity of Pain in Patients With Haemophilia |
|
|
| Completed | N/A | 104 | Europe | Biopsychological pain assessment, Pain-related questionnaires: Brief Pain Inventory, Douleur Neuropathique en 4 questions, Central Sensitization Inventory, Psychological questionnaires: Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Fear Avoidance and Beliefs Questionnaire, The EuroQol-5 (EQ-5D-5L) quality of life questionnaire, Functional questionnaires: Haemophilia Activity List, International Physical Activity Questionnaire (IPAQ), Joint structure: Magnetic Reasoning Imaging (MRI) ankles & ultrasound evaluation of affected joints, Joint function: Hemophilia Joint Health Score (HJHS 2.1), Timed Up & Go, 2 minutes walking test, activity tracker, Somatosensory pain assessment: Quantitative Sensory testing protocol, Conditioned Pain Modulation protocol | Universiteit Antwerpen, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital, Antwerp | Hemophilia A, Hemophilia B | 02/23 | 10/23 | | |
| Havelange, Violaine |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
|
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies |
|
|
| Active, not recruiting | 1/2 | 122 | Europe, US, RoW | Vodobatinib (K0706) capsules | Sun Pharma Advanced Research Company Limited | Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | 08/26 | 08/26 | | |
